Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
1999 1
2000 2
2001 3
2002 4
2003 3
2004 8
2005 11
2006 19
2007 7
2008 9
2009 11
2010 23
2011 14
2012 10
2013 12
2014 9
2015 6
2016 5
2017 4
2018 5
2019 7
2020 2
2021 5
2022 5
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

176 results

Results by year

Filters applied: . Clear all
Page 1
Lasofoxifene in osteoporosis and its place in therapy.
Swan VJ, Hamilton CJ, Jamal SA. Swan VJ, et al. Adv Ther. 2010 Dec;27(12):917-32. doi: 10.1007/s12325-010-0081-y. Epub 2010 Nov 10. Adv Ther. 2010. PMID: 21080249 Review.
Compared with raloxifene, lasofoxifene gave greater decreases in BTMs, and greater increases in lumbar spine BMD. ...At the time of publication, lasofoxifene is not approved for use by the US Food and Drug Administration, and as such is not used in North America....
Compared with raloxifene, lasofoxifene gave greater decreases in BTMs, and greater increases in lumbar spine BMD. ...At the time of p …
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial.
Goetz MP, Bagegni NA, Batist G, Brufsky A, Cristofanilli MA, Damodaran S, Daniel BR, Fleming GF, Gradishar WJ, Graff SL, Grosse Perdekamp MT, Hamilton E, Lavasani S, Moreno-Aspitia A, O'Connor T, Pluard TJ, Rugo HS, Sammons SL, Schwartzberg LS, Stover DG, Vidal GA, Wang G, Warner E, Yerushalmi R, Plourde PV, Portman DJ, Gal-Yam EN. Goetz MP, et al. Ann Oncol. 2023 Dec;34(12):1141-1151. doi: 10.1016/j.annonc.2023.09.3104. Ann Oncol. 2023. PMID: 38072514 Free article. Clinical Trial.
Consistent with target engagement, lasofoxifene reduced ESR1 MAF, and to a greater extent than fulvestrant. Lasofoxifene may be a promising targeted treatment for patients with ESR1-mutated mBC and warrants further investigation....
Consistent with target engagement, lasofoxifene reduced ESR1 MAF, and to a greater extent than fulvestrant. Lasofoxifene may b …
Lasofoxifene: CP 336156, CP-336156.
[No authors listed] [No authors listed] Drugs R D. 2005;6(1):56-60. doi: 10.2165/00126839-200506010-00008. Drugs R D. 2005. PMID: 15801869 Review.
Lasofoxifene [CP 336156] is a potent, nonsteroidal, tissue-selective estrogen receptor modulator (SERM). ...In June 2003, Pfizer reported that enrolment was completed in a trial evaluating lasofoxifene in the prevention of bone loss. The trial also evaluated laso …
Lasofoxifene [CP 336156] is a potent, nonsteroidal, tissue-selective estrogen receptor modulator (SERM). ...In June 2003, Pfizer repo …
Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Lainé M, Fanning SW, Chang YF, Green B, Greene ME, Komm B, Kurleto JD, Phung L, Greene GL. Lainé M, et al. Breast Cancer Res. 2021 May 12;23(1):54. doi: 10.1186/s13058-021-01431-w. Breast Cancer Res. 2021. PMID: 33980285 Free PMC article.
This study investigated the anti-tumor activity of lasofoxifene in breast cancer xenografts expressing Y537S and D538G ERalpha mutants. The combination of lasofoxifene with palbociclib, a CDK4/6 inhibitor, was also evaluated. ...
This study investigated the anti-tumor activity of lasofoxifene in breast cancer xenografts expressing Y537S and D538G ERalpha mutant …
Lasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.
Peterson GM, Naunton M, Tichelaar LK, Gennari L. Peterson GM, et al. Ann Pharmacother. 2011 Apr;45(4):499-509. doi: 10.1345/aph.1P604. Epub 2011 Apr 5. Ann Pharmacother. 2011. PMID: 21467260 Review.
STUDY SELECTION AND DATA EXTRACTION: All clinical trials evaluating lasofoxifene were included in this review. In addition, all articles evaluating the pharmacology, pharmacokinetics, and safety of lasofoxifene in humans were reviewed. ...One 2-year major comparativ …
STUDY SELECTION AND DATA EXTRACTION: All clinical trials evaluating lasofoxifene were included in this review. In addition, all artic …
[Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
Maeda T, Ke HZ, Simmons H, Thompson D. Maeda T, et al. Clin Calcium. 2004 Oct;14(10):85-93. Clin Calcium. 2004. PMID: 15577137 Review. Japanese.
In studies designed to investigate the combination of lasofoxifene with estrogen, lasofoxifene blocked the hypertrophic effects of estrogen in the uterus, but did not block the bone protective effects. ...In preclinical studies designed to evaluate the effects of …
In studies designed to investigate the combination of lasofoxifene with estrogen, lasofoxifene blocked the hypertrophic effect …
Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis.
Gennari L. Gennari L. Drugs Today (Barc). 2006 Jun;42(6):355-67. doi: 10.1358/dot.2006.42.6.973583. Drugs Today (Barc). 2006. PMID: 16845439 Review.
Moreover, due to increased resistance to intestinal wall glucuronidation, lasofoxifene has a remarkably improved oral bioavailability with respect to other SERMs. In both preclinical and short-term clinical studies lasofoxifene has shown a proven efficacy in prevent …
Moreover, due to increased resistance to intestinal wall glucuronidation, lasofoxifene has a remarkably improved oral bioavailability …
Lasofoxifene (Pfizer).
Gennari L. Gennari L. Curr Opin Investig Drugs. 2005 Oct;6(10):1067-78. Curr Opin Investig Drugs. 2005. PMID: 16259229 Review.
Pfizer is developing lasofoxifene, an oral naphthalene derivative selective estrogen receptor modulator identified under a collaboration with Ligand, for the treatment of osteoporosis and vaginal atrophy. In August 2004, Pfizer submitted a New Drug Application to the Food …
Pfizer is developing lasofoxifene, an oral naphthalene derivative selective estrogen receptor modulator identified under a collaborat …
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.
Damodaran S, O'Sullivan CC, Elkhanany A, Anderson IC, Barve M, Blau S, Cherian MA, Peguero JA, Goetz MP, Plourde PV, Portman DJ, Moore HCF. Damodaran S, et al. Ann Oncol. 2023 Dec;34(12):1131-1140. doi: 10.1016/j.annonc.2023.09.3103. Ann Oncol. 2023. PMID: 38072513 Free article. Clinical Trial.
PATIENTS AND METHODS: In the open-label, phase II, ELAINE 2 trial (NCT04432454), women with ESR1-mutated, ER+/human epidermal growth factor receptor 2-negative (HER2-) mBC who progressed on prior therapies (including CDK4/6i) received lasofoxifene 5 mg/day and abemaciclib …
PATIENTS AND METHODS: In the open-label, phase II, ELAINE 2 trial (NCT04432454), women with ESR1-mutated, ER+/human epidermal growth factor …
Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis.
Gennari L, Merlotti D, Martini G, Nuti R. Gennari L, et al. Expert Opin Investig Drugs. 2006 Sep;15(9):1091-103. doi: 10.1517/13543784.15.9.1091. Expert Opin Investig Drugs. 2006. PMID: 16916275 Review.
This article reviews lasofoxifene, a new-generation selective estrogen receptor modulator (SERM) that is currently in Phase III development for the prevention and treatment of osteoporosis in postmenopausal women. ...Dose modelling from Phase II studies allowed the selecti …
This article reviews lasofoxifene, a new-generation selective estrogen receptor modulator (SERM) that is currently in Phase III devel …
176 results